SVA — Sernova Biotherapeutics Share Price
0.000.00%
Last trade - 00:00- CA$62.41m
- CA$61.75m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Oct | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | n/a | n/a | n/a | n/a | n/a | 15 | 0.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.
Directors
- Frank Holler NEC (64)
- Philip Toleikis PRE
- David Swetlow CFO
- Delfina Siroen OTH
- Mohammad Azab IND (65)
- Jeffrey Bacha IND (51)
- Deborah Brown IND
- James Parsons IND (55)
- Last Annual
- October 31st, 2024
- Last Interim
- January 31st, 2025
- Incorporated
- February 4th, 2025
- Public Since
- April 29th, 1999
- No. of Employees
- 17
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- Toronto Stock Exchange
- Shares in Issue
- 328,484,786
- Address
- 700 Collip Circle, Ste 114, LONDON, N6G 4X8
- Web
- https://sernova.com/
- Phone
- +1 5198585184
- Auditors
- KPMG LLP
Upcoming Events for SVA
Q2 2025 Sernova Corp Earnings Release
Similar to SVA
Bausch + Lomb
Toronto Stock Exchange
Healwell Al
Toronto Stock Exchange
Profound Medical
Toronto Stock Exchange
Vitalhub
Toronto Stock Exchange
FAQ
What is the Sernova Biotherapeutics share price?
As of Today at 23:10 UTC, shares in Sernova Biotherapeutics are trading at CA$0.19. This share price information is delayed by 15 minutes.
How has the Sernova Biotherapeutics share price performed this year?
Shares in Sernova Biotherapeutics last closed at CA$0.19 and the price had moved by -55.29% over the past 365 days. In terms of relative price strength the Sernova Biotherapeutics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -60.25% over the past year.
What are the analyst and broker recommendations for Sernova Biotherapeutics?
The overall consensus recommendation for Sernova Biotherapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Sernova Biotherapeutics dividend yield?
Sernova Biotherapeutics does not currently pay a dividend.
Does Sernova Biotherapeutics pay a dividend?
Sernova Biotherapeutics does not currently pay a dividend.
When does Sernova Biotherapeutics next pay dividends?
Sernova Biotherapeutics does not currently pay a dividend.
How do I buy Sernova Biotherapeutics shares?
To buy shares in Sernova Biotherapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Sernova Biotherapeutics?
As of the previous close price of CA$0.19, shares in Sernova Biotherapeutics had a market capitalisation of CA$62.41m.
Where are Sernova Biotherapeutics shares listed?
Here are the trading details for Sernova Biotherapeutics:
- Country of listing: Canada
- Exchange: TOR
- Ticker Symbol: SVA
What kind of share is Sernova Biotherapeutics?
Based on an overall assessment of its quality, value and momentum Sernova Biotherapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Sernova Biotherapeutics share price forecast for 2025?
The analyst consensus target price for shares in Sernova Biotherapeutics is CA$2.50. That is 1215.79% above the last closing price of CA$0.19.
Analysts covering Sernova Biotherapeutics currently have a consensus Earnings Per Share (EPS) forecast of -CA$0.04 for the next financial year.
Find out moreWhat is the trend in the Sernova Biotherapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sernova Biotherapeutics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -24.45%.
As of the last closing price of CA$0.19, shares in Sernova Biotherapeutics were trading -17.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Sernova Biotherapeutics PE Ratio?
The Sernova Biotherapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.19.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Sernova Biotherapeutics?
Sernova Biotherapeutics' management team is headed by:
- Frank Holler - NEC
- Philip Toleikis - PRE
- David Swetlow - CFO
- Delfina Siroen - OTH
- Mohammad Azab - IND
- Jeffrey Bacha - IND
- Deborah Brown - IND
- James Parsons - IND